The effective management of snakebites, particularly from species like the monocled cobra (Naja kaouthia), is critical due to the severe medical implications associated with their venom. Recent studies highlight the need for region-specific and species-specific anti venoms to improve outcomes for snakebite victims.
The treatment of monocle cobra bites demands a shift towards the development of region-specific anti venoms that adequately reflect the proteomic variability of snake venoms across different populations. There is a pressing need for coordinated efforts in research and clinical practice to bolster the efficacy of ant venoms therapies and enhance patient outcomes for snakebite victims. Regaining comprehensive epidemiological data and improving anti venom formulations will be crucial in addressing this neglected health issue effectively.
The researchers measured venom-specific antibodies in commercial antivenoms and found lack of such antibodies against NKV in the commercial samples. Hence the lethality and toxicity of different NKV samples were not effectively neutralized by commercial polyvalent antivenom (PAV). The study published in the Elsevier journal Toxicon, has recommended inclusion of species specific and region-specific antibodies against NKV in commercial PAV mixture for better management of NK envenomation.
Besides, the researchers have also suggested clinical investigations on NK envenomation in areas where the snake is commonly found and assessment of the relationship between this information and the local NKV composition.
Improvement of the current immunization protocol to promote the production of antibodies against less immunogenic venom components of this snake as well as better and more effective hospital management of NK envenomation could help improve measures for treating snake bites.
Publication Link: https://doi.org/10.1016/j.toxicon.2024.108056